Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721030 | 0.91 | TSHR (0.36) | PAX8LMNA | |
| SCHEMBL5981837 | 0.90 | MAPT (0.39) | LMNA | |
| SCHEMBL17748583 | 0.86 | PAX8 (0.36) | PAX8 | |
| SCHEMBL1821447 | 0.84 | LMNA (0.33) | LMNAKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL6472262 | 0.82 | LMNA (0.34) | LMNAKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL17748555 | 0.82 | PAX8 (0.34) | PAX8 | |
| SCHEMBL5355000 | 0.82 | PAX8 (0.37) | PAX8 | |
| SCHEMBL17748597 | 0.82 | GRM8 (0.41) | PAX8LMNAKDM2A | |
| SCHEMBL20889 | 0.82 | PAX8 (0.36) | PAX8 | |
| SCHEMBL9807659 | 0.82 | PAX8 (0.36) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585988-B2 | Anchorage devices comprising an active pharmaceutical ingredient | TYRX, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-12447242-B2 | Hemostatic devices and methods of use | MEDTRONIC, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3452126-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250262358-A1 | SURGICAL SYSTEM AND METHODS OF USE | MEDTRONIC INC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-3452125-B1 | CUSTOMIZABLE ANCHORAGE DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250152332-A1 | SURGICAL SYSTEM AND METHODS OF USE | MEDTRONIC, INC. | 2025-05-15 | — | — | US | disclosed |
| US-12168085-B2 | Surgical system and methods of use | MEDTRONIC, INC (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168086-B2 | Hemostatic devices and methods of use | MEDTRONIC, INC (US) | 2024-12-17 | — | — | US | disclosed |
| US-20090018559-A1 | Temporarily Stiffened Mesh Prostheses | TYRX PHARMA, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008127411-A1 | MESH POUCHES FOR IMPLANTABLE MEDICAL DEVICES | TYRX PHARMA, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008121816-A2 | BIODEGRADABLE, POLYMER COVERINGS FOR BREAST IMPLANTS | TYRX PHARMA, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080241212-A1 | Tyrosine-derived aromatic polyester sheet, film or mat of nanofibers optionally including anesthetics, antiinflammatories, microbiocides, leukotriene inhibitors, or antiscarring, antifibrotic, or antineoplastic agents, and that resists capsular contracture and adherence to the implant | TYRX PHARMA, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080132922-A1 | Mesh Pouches for Implantable Medical Devices | TYRX PHARMA, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080128315-A1 | Biodegradable polylactic acid polymer pouches for pacemaker, defibrillator, pulse generator cardiac rhythm mamagent devices; antimicrobial agents, anesthetics, anti-inflammatory agents, anti-scarring drugs in polymer matrix; barrier to microbial colonization of medical device during surgical implantation | TYRX PHARMA, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080089941-A1 | Fucoidan compositions and methods | SAKURA PROPERTIES, LLC | 2008-04-17 | — | — | US | disclosed |
| WO-2007140022-A2 | FUCOIDAN COMPOSITIONS AND METHODS | SAKURA PROPERTIES, LLC (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070198040-A1 | Temporarily Stiffened Mesh Prostheses | TYRX PHARMA INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-6579544-B1 | Blends of vitamins, minerals, carotenoids, flavinoids, glucosamine, chondroitin sulfate, lipoic acid/-A/, coenzyme Q10 and linseed oils for preventing diseases such as degenerative joint disease | NUTRIEX, L.L.C. | 2003-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168086-B2 | Hemostatic devices and methods of use | PLAT, HABP2, F2 | PAX8 1172/4885LMNA 638/4885KDM6B 1148/4885 |
| US-12168085-B2 | Surgical system and methods of use | FGB, F2, COL14A1 | PAX8 2696/4885LMNA 488/4885KDM6B 2741/4885 |
| US-12447242-B2 | Hemostatic devices and methods of use | HABP2, PLAT, F2 | PAX8 1696/4885LMNA 624/4885KDM6B 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.